Long-term Extension Study of Ligelizumab in Food Allergy

Key Inclusion Criteria:

• Signed informed consent and or/assent (where applicable) obtained fromparticipant/legal representative prior to enrolling in the rollover study andreceiving study medication. If a minor participant providing assent reached the ageof legal majority (as defined by local law), he/she was to be re-consented at thenext study visit.

• Participants had completed the treatment period in any ligelizumab's Phase IIIstudies in food allergy.

• Participants who were willing to adhere to the study visits and procedures,including receiving injections (study treatment) and participating in the OL-OFC (open label oral food challenge).

• Participants who agreed to continue avoiding exposure to allergens (per core study)and any other foods they were allergic to throughout this study.

• Participants who were able to safely continue into the study as judged by theinvestigator.

Key Exclusion Criteria:

• Development of a severe or life-threatening episode of an allergic reaction thatrequired intubation and/or intensive care unit (ICU) admission during the corestudies.

• Development of a serious adverse event which was suspected to be related to thestudy treatment judged by the investigator during the core study.

• Development of uncontrolled asthma during the core study that compromised the safetyof the participants judged by the investigator.

• Development of clinically significant cardiovascular, neurological, and orpsychiatric conditions during the core study that could interfere with or compromisethe safety of the participants, interfere with evaluation or interpretation of thestudy results or preclude completion of the study judged by the investigator.

• Participants who failed to comply with the protocol requirements and proceduresduring the core study, and in the Investigator's opinion, should not participate inthis extension study.

• Platelets <75,000/ul at end of treatment of the core study.